Kibur Science Spotlight: Identifying the Additive and Synergistic Effects of Combination Immunotherapy Treatments in a Renal Cell Cancer Patient Derived Xenograft Model
Identifying how to optimally combine immunotherapies with other available anti-cancer therapies and identifying biomarkers predictive of response is a major challenge in oncology. Traditionally, only one potential combination can be examined per mouse in a systemic dosing study, and large cohorts are needed to draw statistically significant conclusions on its efficacy. The different cellular pathways modulated by a drug combination will likely manifest in a pattern of protein and gene expression as indicators of tumor response as opposed to the change in expression of a single gene or protein. A systematic method to screen many potential combination therapies and measure the intratumor molecular response in a small animal cohort has remained elusive. Our recent study examines the NanoNail’s™ role in de-risking drug development and enabling Phase 0 microdose testing.
For more information, find the study here: https://pubmed.ncbi.nlm.nih.gov/35129472/